LSC
CRL icon

Lyon Street Capital’s Charles River Laboratories CRL Stock Holding History

Lyon Street Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.28M Sell
4,500
-300
-6% -$92.5K 1.91% 10
2021
Q4 		$1.81M Buy
+4,800
New +$1.86M 1.8% 1
2020
Q3 		$962K Buy
+4,250
New +$882K 2.86% 7

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lyon Street Capital's CRL Position: Q1 2022 in Review

Lyon Street Capital reduced its Charles River Laboratories (CRL) stake by 6.3% in Q1 2022, selling an estimated $92.5K and leaving 4,500 shares worth $1.28M. The position accounts for 1.91% of the portfolio, ranked #10.

Lyon Street Capital first reported a position in CRL in Q3 2020 and has held it in 3 quarters since. The position peaked at $1.81M in Q4 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Lyon Street Capital held 4,500 shares of Charles River Laboratories worth $1.28M as of Q1 2022.
  • Lyon Street Capital sold 300 Charles River Laboratories shares in Q1 2022, an estimated $92.5K.
  • Charles River Laboratories made up 1.91% of Lyon Street Capital's portfolio in Q1 2022, its #10 holding.
  • Lyon Street Capital first reported a position in Charles River Laboratories in Q3 2020 and has held it in 3 quarters since.
  • Lyon Street Capital's Charles River Laboratories position peaked at $1.81M in Q4 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Lyon Street Capital's 13F filing for Q1 2022, filed 16 May 2022.